Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2/erbB2). Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy. Data from clinical trials are consistently showing the key role of this agent in the management of HER2-positive disease. Moreover, interesting data are suggesting a key role of lapatinib in enhancing endocrine responsiveness and/or restoring endocrine sensitivity in hormone receptorpositive disease. The present article will summarize the main data leading to the clinical development of the combination of lapatinib and the aromatase inhibitor letrozole.

Original languageEnglish
Pages (from-to)1549-1557
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 2009

Keywords

  • Advanced breast cancer
  • HER2 positive
  • Hormone receptor positive
  • Lapatinib
  • Letrozole
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer'. Together they form a unique fingerprint.

Cite this